Clinical Research Details

Descriptive Information
Oral dydrogesterone versus vaginal progesterone in the luteal phase support in cryo-warmed embryo transfer cycles : A retrospective study

Johnny Awwad



Phase 0  

Layal Hamdar
Extension: 5606
Conditions and Keywords
cryo-warmed embryo transfer,luteal phase support
Study Design
Safety and/or Efficacy Study
N/A: Not Applicable
N/A: Not Applicable
N/A: Not Applicable
N/A: Not Applicable
Eligibility and IRB
Min: 18
Max: 42

In IVF/ICSI cycles, progesterone levels prompted by ovarian stimulation are low; therefore the luteal phase is supported by progesterone. A standard protocol for luteal phase support has not yet been established. There is currently a wide use of vaginal progesterone, since oral progesterone results in lower pregnancy rates. However, vaginal administration of progesterone is associated with several adverse events such as vaginal irritation, discharge and bleeding. For all these reasons, there is a need for an effective, well tolerated, and safe treatment that can improve patient satisfaction and compliance. The objective of our study is to compare the use oral dydrogesterone (Duphaston) and vaginal progesterone (Utrogestan) for luteal supplementation in cryo-warmed embryo transfer cycles, along with the potential adverse events or harm associated with each.

This retrospective observational study will review the archived charts of all of Dr. Johnny Awwad’s patients who underwent cryo-warmed embryo transfer cycles at the AUBMC Fertility Center at the American University of Beirut Medical Center between August 2016 and August 2018

Age: 18-42 years at the time of interview.
Normal uterine cavity (as assessed by hysteroscopy or HSG).
Normal hormonal investigation: TSH, PRL.
Undergoing a cryo-warmed embryo transfer cycle
Body mass index (BMI) ≥18 to ≤30 kg/m2 .

Preexisting untreated medical condition (thyroid disease, diabetes mellitus, hypertension, pulmonary conditions, cardiac condition…).
History of three or more previous IVF failures.
History of three or more miscarriages.
Previous allergy reactions to progesterone products.